Showing results (1-10 of 512) with videos related to
Sort By:
Pageof 52
Cancer Cell|October 14, 2015
Shifting the Evolving CAR T Cell Platform into Higher GearDaniel R Holohan, James C Lee, Jeffrey A BluestonePlos One|October 25, 2019
Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse modelDaniel R Holohan, Frédéric Van Gool, Jeffrey A BluestoneFrontiers in Medicine|January 12, 2019
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin CancerJennifer A Bridge, James C Lee, Adil Daud, et al.Nature Reviews. Immunology|March 19, 2005
Regulatory T-cell therapy: is it ready for the clinic?Jeffrey A BluestoneCancer Discovery|March 3, 2021
At the Heart of Immune Checkpoint Inhibitor-Induced Immune ToxicityArabella Young, Jeffrey A BluestoneImmunological Reviews|August 15, 2006
Regulatory T-cell physiology and application to treat autoimmunityQizhi Tang, Jeffrey A BluestoneCell Stem Cell|October 2, 2020
Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 DiabetesJeffrey A Bluestone, Qizhi TangCurrent Opinion in Immunology|October 8, 2005
How do CD4+CD25+ regulatory T cells control autoimmunity?Jeffrey A Bluestone, Qizhi TangEuropean Journal of Immunology|April 13, 2007
Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative diseaseShunsuke Chikuma, Jeffrey A BluestoneCold Spring Harbor Perspectives in Medicine|November 5, 2013
Regulatory T-cell therapy in transplantation: moving to the clinicQizhi Tang, Jeffrey A BluestonePageof 52